Dan Marquess, D. Phil

Chief Scientific Officer

Dan is Chief Scientific Officer at UNITY, leading the Company’s effort to create novel senolytic molecules for the treatment of diseases of aging. Prior to UNITY, Dan was Vice President and Head of Medicinal Chemistry at Theravance Biopharma, where he led the chemistry department to leverage Theravance’s multivalent approach to drug discovery. He was a scientific leader within Research Leadership Team when the Theravance research group progressed six molecules into clinical development. These include a JAK inhibitor (TD-1473 for gastrointestinal inflammation), a NEP inhibitor (TD-0714 for cardiovascular disease), a NS5α inhibitor (TD-6450 for hepatitis C), a monoamine reuptake inhibitor (TD-9855 for fibromyalgia) and a 5-HT4 agonist (TD-8954 for gastrointestinal disorders of reduced motility). Dan was Head of Medicinal Chemistry when axelopran (TD-1211 a peripheral μ-opioid antagonist for opioid-induced constipation) and revefenacin (TD-4208 for COPD) progressed into clinical development. Dan was part of Theravance’s team for two FDA Advisory Committee Meetings for VIBATIV™ (telavancin for the treatment of Complicated Skin & Skin Structure Infections and telavancin for the treatment of Nosocomial Pneumonia). Dan was the project team leader that initiated the gastrointestinal motility program. Dan led the project team that discovered and developed Theravance’s selective 5-HT4 agonist velusetrag, currently in clinical development for gastroparesis. Dan also led the medicinal chemistry team that discovered the glycopeptide-cephalosporin Gram positive antibacterials, TD-1792 and TD-1607. Prior to joining Theravance in 1998, Dan worked at GlaxoSmithKline, Stevenage, UK as a medicinal chemist in the neuroscience discovery unit. Dan is a graduate of the Queen’s University, Belfast, Northern Ireland, where he holds a B. Sc. (1st Class Hons) in Chemistry. He holds a D. Phil. in Organic Chemistry from the University of Oxford with Sir Professor J. E. Baldwin, FRS. He was awarded a NATO postdoctoral fellowship to conduct chemistry research with Professor Paul A. Wender at Stanford University where he was part of the Stanford synthetic team that completed the total synthesis of the anticancer agent, Taxol. He has authored ~41 papers published in peer-reviewed journals and is an inventor on ~19 patents. He also acts as pharmaceutical discovery advisor to the The Wellcome Trust, the second largest biomedical charitable organization in the world.